VanEck Biotech ETF

ProShare Advisors Increases Gilead Stake by 39.1% in Q4, Total Holdings Reach 2.2 Million Shares

Gilead Sciences Chief Communications Officer Johanna Mercier Sells Nearly 28k Shares for $3.55M

United Therapeutics Announces Tyvaso Met Primary Endpoint in IPF Phase 3 Trial, Plans FDA Submission for New Indication

Truist Financial Cuts Regeneron Price Target, Sending Shares Gap Down

Regeneron's fianlimab combination fails Phase 3, shares plunge over 11%

Regeneron Partners with Parabilis for $125M Deal to Advance Antibody Conjugates

TD Cowen Analyst Thome Reaffirms Buy Rating on United Therapeutics with $675 Target

United Therapeutics announces Phase III trial success for ralinepag, plans FDA submission in late 2026

Revolution Medicines Pancreatic Cancer Drug Trial Shows Positive Results, US Cancer Center Launches Expanded Access Plan Amid Stock Fluctuation

Gilead Sciences Focuses on HIV Growth and Expands Oncology and Inflammation Pipeline via Acquisitions

United Therapeutics CFO James Edgemond Sells 10,000 Shares for $5.74 Million

Natera Co-founder Sheena Jonathan Sells Shares in Two Transactions in May

Regeneron Provides Update on Phase 3 Trial of Fianlimab Combination for Melanoma

Combination Therapy Approved by FDA to Launch Pig-Derived UHeart Xenotransplant Clinical Trial

Signatera™ CDx Receives FDA Approval as Companion Diagnostic for Muscle-Invasive Bladder Cancer

Oppenheimer Raises Biogen Price Target to $300, Maintains Outperform Rating

Gilead Sciences Prices $3 Billion Senior Unsecured Bond Offering

TD Cowen Reaffirms Buy Rating on Biogen with $215 Price Target

Biogen Finalizes Acquisition Agreements with Apellis: Establishes SYFOVRE Milestone CVR and Secures $2 Billion Loan

Biogen Advances Alzheimer's Drug to Late Trials Despite Mid-Stage Failure, Shares Jump 6%

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

NextNRG

InMed Pharmaceuticals

Amesite

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

Meiwu Tech

CN Energy

MetaVia

Generation Income Properties

Co-Diagnostics

Pinned News

置顶新闻

EXCLUSIVE: Hoth Therapeutics To Rebrand To Pursue AI Chip Technologies

HOTH

LABU

Hoth Therapeutics Inc. plans to rebrand as Rocket One Inc. to focus on AI semiconductor technologies and ultra-low-power AI computing. The board unanimously approved this strategic shift, which includes securing exclusive rights to technologies from Virginia Commonwealth University. The company will maintain its biotechnology operations while addressing AI infrastructure challenges. Hoth's shares fell 9.69% to $0.55 in premarket trading, reflecting a 20.9% decline over the past month.

benzinga_article

Hoth Therapeutics

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

S&P 500

CODX

SBIO

Co-Diagnostics Inc. (CODX) has developed a Bundibugyo virus assay for rapid detection amid escalating Ebola outbreak alerts. Following WHO's emergency declaration, the company emphasizes the importance of decentralized diagnostics and rapid PCR testing. CEO Dwight Egan highlighted the need for quick mobilization in response to infectious diseases, shaped by lessons from COVID-19. The company is prepared for collaboration on future assay development. CODX shares are currently trading at $2.07, up 51.09%.

nasdaq

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

Nasdaq

Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up

513700

159859

ARKG

Ipsen announced findings from the Phase IV DIRECTION trial comparing Dysport and Botox for upper limb spasticity. The results, presented at the ISPRM congress in Vancouver on May 19, 2026, showed Dysport had a similar safety profile to Botox and offered longer-lasting symptom relief.

Unusual Whales

Penghua CSI HK Connect Health Care Composite ETF

Tianhong CNI BIOMEDICINE ETF

Proshares UltraShort Nasdaq Biotech

China Southern Hang Seng Biotech ETF(QDII)

iShares US Pharma

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC SSE STAR Biology and Medicine ETF

ChinaAMC CSI Biotechnology Theme ETF

Bosera Hang Seng Health Care ETF(QDII)

E Fund CSI 300 Health Care ETF

Invesco Nasdaq Biotechnology ETF

iShares Global Healthcare

VG Health

BlackRock, Inc.

E Fund CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

Guotai CSI Bio-medicine ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

China Merchants CSI Biotechnology Theme ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

E Fund Hang Seng SCHK Innovative Drug ETF

Penghua SSE STAR Biology and Medicine ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Minsheng Royal CSI Biotechnology Theme ETF

Health Care Select Sector SPDR

Huaan Hang Seng Biotech ETF

Ark Genomic Revolution ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Ipsen announces late-breaking data from first head-to-head study comparing Dysport® and Botox® in adults with upper limb spasticity

SVRA

Savara's corporate presentation highlighted Phase 3 IMPALA-2 data for MOLBREEVI, showing significant improvement in DLCO% at Week 24 and sustained gains at Week 48 versus placebo. Patient-reported outcomes also improved at Week 24. The FDA BLA PDUFA date for MOLBREEVI is set for Nov. 22, 2026, with the drug still unapproved.

PUBT

Savara

Savara publishes corporate presentation focused on autoimmune PAP and MOLBREEVI program

Altesa BioSciences presented positive results from a Phase 2 challenge study of vapendavir for COPD patients at the ATS 2026 conference. The study showed reduced viral load, inflammation, and improved patient outcomes after rhinovirus infection. Vapendavir may shift treatment from reactive to preemptive, addressing a significant unmet need in chronic lung disease. Altesa has initiated a Phase 2b CARDINAL study to further evaluate vapendavir's efficacy and safety in COPD patients with rhinovirus, aiming to enroll 900 participants across the US and UK.

prnewswire

14:51 ETAltesa BioSciences Presents Positive Phase 2 Challenge Study Results for Vapendavir at American Thoracic Society International Conference 2026

SLXNW

SLXN

Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds

SILEXION THERAPEUTICS CORP C/WTS EXP 15/08/2029 (TO PUR COM)

Silexion Therapeutics

Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds

MEDP

Medpace Holdings shareholders approved charter amendments to remove supermajority voting requirements and limits on calling special meetings during the annual meeting on May 15, 2026. The changes will take effect on May 18, 2026. Additionally, shareholders owning at least 25% of voting power can now call special meetings, subject to certain conditions. A non-binding proposal for calling special meetings did not pass.

Medpace

iShares Genomics Immunology and Healthcare ETF

Medpace Holdings shareholders approve charter amendments removing supermajority voting requirements

Savara presented 48-week data from the Phase 3 IMPALA-2 trial at the ATS International Conference 2026, showing long-term efficacy and safety of molgramostim in aPAP. Results indicated sustained lung function improvement and quality of life in patients on molgramostim, with those switching from placebo also showing benefits. The safety profile was consistent with previous trials, and 160 out of 164 enrolled patients completed the study, indicating strong retention.

Savara reports 48-week open-label IMPALA-2 data for molgramostim in aPAP

Saturn V Capital Management sold 822,007 shares of Dyne Therapeutics for approximately $14.17 million, reducing its stake to 966,609 shares valued at $17.52 million. Despite this sale, Dyne's stock has risen nearly 40% over the past year, outperforming the S&P 500. The company is focused on developing therapeutics for rare muscle diseases and has a strong cash position of $972.2 million, funding operations into 2028. Investors are advised to consider other stocks as Dyne was not included in a recent top 10 list by The Motley Fool.

Dyne Therapeutics

Alumis

Amylyx Pharmaceuticals

Abivax SA

Vaxcyte

Pharvaris BV

Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares

OCUL

Saturn V Capital Management fully exited its position in Ocular Therapeutix, selling 1,504,880 shares for an estimated $14.34 million. The fund's reported assets fell by $18.27 million due to share sales and price changes. Ocular's recent performance has been mixed, with revenue growth lagging and net losses widening, despite positive clinical trial data. Investors are advised to consider other stocks, as Ocular was not included in a recent top investment list.

Ocular Therap

Netflix

NVIDIA

NVIDIA Corporation

What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors

ENVB

Enveric Biosciences shares are trading lower. The company announced preclinical in vitro results showing no photoreactive potential for EB‑003, further derisking its neuropsychiatric program.

Enveric Biosciences

VanEck Biotech ETF(BBH.US)

EXCLUSIVE: Hoth Therapeutics To Rebrand To Pursue AI Chip Technologies

Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up

Ipsen announces late-breaking data from first head-to-head study comparing Dysport® and Botox® in adults with upper limb spasticity

Savara publishes corporate presentation focused on autoimmune PAP and MOLBREEVI program

14:51 ETAltesa BioSciences Presents Positive Phase 2 Challenge Study Results for Vapendavir at American Thoracic Society International Conference 2026

Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds

Medpace Holdings shareholders approve charter amendments removing supermajority voting requirements

Savara reports 48-week open-label IMPALA-2 data for molgramostim in aPAP

Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares

What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors

Enveric Biosciences shares are trading lower. The company announced preclinical in vitro results showing no photoreactive potential for EB‑003, further derisking its neuropsychiatric program.